Lupus

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.

This rheumatology month in review emphasizes new data from the ACR Convergence.

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

Jin discussed new evidence supporting the immune-modulating effects of low-dose IL-2 at ACR 2025.

Obinutuzumab was approved earlier in October for LN under the name Gazyva.

A recent exploratory analysis reveals significant kidney B-cell depletion by the recently approved drug.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and colorectal cancer screening updates, in this week's essential news roundup.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

The decision is supported by positive results from the phase 2 NOBILITY and phase 3 REGENCY studies.

However, a notable higher rate of treatment-related adverse events warrants caution.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Nearly a third of patients with lupus in APPEAL reported falls, with disease activity, depressive symptoms, and medication use among key risk factors.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

This session at the DERM 2025 conference highlights several clinical pearls in dermatology and was presented by rheumatologist Karim Ladak, MD.

New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.

This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.

An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.

With the approval, children ≥ 5 years of age with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.

Recent studies reveal belimumab's effectiveness in treating lupus nephritis, showing significant renal response and improved patient outcomes in real-world settings.

Sayna Norouzi, MD, reflects on the recent progress in the therapeutic pipeline for lupus nephritis.